EDAP Announces Exclusive Distribution Agreement with Leading Italian Medical Device Distributor AB Medica
- Partnership further extends the availability of EDAP’s High Intensity Focused Ultrasound (HIFU) technology to one of the largest markets in Europe
- Complementary to AB Medica’s extensive product portfolio which includes robotic surgery solutions as well as ExactVu
LYON, France, November 17, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today that the company has signed an exclusive distribution agreement with AB Medica, a leading distribution of medical technologies across Italy.
Marc Oczachowski, Chairman and Chief Executive Officer of EDAP, commented: “We are very pleased to partner with AB Medica, a widely recognized leader in Italy for the distribution of cutting-edge medical technologies. This is clearly a step forward for EDAP in its HIFU adoption and commercialization program in Europe, as Italy is the fourth largest market for medical devices. Notably, AB Medica had already been distributing ExactVu, so they are familiar with our product line and have been able to incorporate Focal One very quickly. AB Medica also has extensive experience in the distribution of robotic prostate surgery solutions, so they are the perfect fit for us. We look forward to a very successful partnership.”
Filippo Pacinotti, Business Director of AB Medica, stated: “We are thrilled to have entered into this distribution agreement with EDAP, which is already a highly recognized name in Italy. This partnership will not only see us strengthen our presence in high definition ultrasound with ExactVu, but will also give us the opportunity to become a reference point in lithotripsy and HIFU, rounding out what will be an outstanding urology product portfolio. We are confident that we will meet EDAP’s expectations, and we are eager to start this new adventure with great enthusiasm.”
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit , and .
About AB Medica
Founded in 1984 by Aldo Cerruti, still the company’s President, ab medica is now Italy’s leading company in the production and distribution of medical technologies, as well as a reference point for robotic surgery and technological innovation in healthcare. Excellence, quality, technological innovation and competitiveness all rotate around our single mission which is to put people and their wellbeing at the centre of every one of our activities. Thanks to its synergistic collaboration with other companies in the holding, ab medica has now acquired a leading role in the field of Research & Development, with important projects and solutions in sectors such as genomics, tissue engineering and stem cells, together with intensified relations with universities, research centres and international scientific laboratories. For more information on the company, please visit their website
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
50
Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
